Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Midazolam kinetics.

H Allonen, G Ziegler, U Klotz

    Clinical Pharmacology and Therapeutics
    |November 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Midazolam, a new benzodiazepine, is rapidly absorbed orally but has low bioavailability due to significant first-pass metabolism. Plasma drug levels correlate well with its sedative effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The effect of increasing dietary palmitic and stearic acid on melting properties of milk fat from Holstein cows.

    Journal of dairy science·2025
    Same author

    SMAS: Structural MRI-based AD Score using Bayesian supervised VAE.

    Computers in biology and medicine·2025
    Same author

    Gaussian Process-based prediction of memory performance and biomarker status in ageing and Alzheimer's disease-A systematic model evaluation.

    Medical image analysis·2023
    Same author

    Data integration for identification of important transcription factors of STAT6-mediated cell fate decisions.

    Genetics and molecular research : GMR·2016
    Same author

    Estimating anatomical trajectories with Bayesian mixed-effects modeling.

    NeuroImage·2015
    Same author

    Individualized Gaussian process-based prediction and detection of local and global gray matter abnormalities in elderly subjects.

    NeuroImage·2014
    Same journal

    The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy

    Background:

    • Midazolam is a novel benzodiazepine with potential applications in sedation and anesthesia.
    • Understanding its pharmacokinetic and pharmacodynamic profile is crucial for safe and effective clinical use.

    Purpose of the Study:

    • To characterize the effect-kinetics of midazolam following oral and intravenous administration.
    • To determine the bioavailability, metabolism, and elimination pathways of midazolam.

    Main Methods:

    • Six healthy subjects received single oral (7.5 and 15 mg) and intravenous (0.075 mg/kg) doses of midazolam.
    • Plasma protein binding, urinary excretion, and elimination half-life (t1/2 beta) were measured.
    • Bioavailability, absorption rate (t1/2abs), and total body clearance were calculated.
    • Correlation between plasma midazolam levels and dynamic effects (d2 letter cancellation test, sedation index) was assessed.

    Related Experiment Videos

    Main Results:

    • Midazolam is highly bound to plasma proteins (94%) with minimal unchanged urinary excretion (<0.5%).
    • Rapid hepatic elimination was observed, with a t1/2 beta of 2.4 +/- 0.8 hr and high total body clearance.
    • Oral bioavailability was limited to 44% due to a substantial first-pass effect, despite rapid absorption (t1/2abs = 0.23 +/- 0.37 hr).
    • Strong intraindividual linear correlations (r=0.68-0.97) were found between plasma concentrations and observed sedative effects.

    Conclusions:

    • Midazolam exhibits rapid absorption and elimination, characteristic of benzodiazepines.
    • Significant first-pass metabolism markedly reduces oral bioavailability.
    • A clear relationship exists between midazolam plasma levels and its pharmacodynamic effects, supporting its use as a sedative agent.